BIOA · Program file
BGE-102
When did BioAge Labs, Inc. say BGE-102 results would come?
On , BioAge Labs, Inc. wrote in its SEC Form 10-Q: “We anticipate reporting topline data from QUELL-CV in the second half of 2026.” (Source)
Days left in the window the company stated: 73 · company’s wording: “second half of 2026”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- BGE-102
- Other names in filings
- QUELL-CV
- Indication in the filing
- obesity and baseline inflammation at elevated cardiovascular risk
- Trials named in the same filing
- None listed
- Latest timing wording
- “We anticipate reporting topline data from QUELL-CV in the second half of 2026.”
- Source
- 10-Q · filed · SEC accepted · accession 0001193125-26-335407 · SEC original
- Last checked
Program BIOA-bge-102.